8-甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚 | 64172-41-4

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 8-甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚
• 英文名称: 8-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
• CAS: 64172-41-4
• 化学式: C₁₂H₁₄N₂
• mdl: MFCD05663532
• 分子量: 186.257
• InChiKey: ZZNXMXVBVZSXEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H317

反应信息

• 作为反应物：
  描述：

  8-甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚 在 盐酸 、 caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 ethyl 2-(8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetate hydrochloride
  参考文献：
  名称：

  Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist

  摘要：

  Herein we describe the discovery of the novel CRTh2 antagonist 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid 28 (setipiprant/ACT-129968), a clinical development candidate for the treatment of asthma and seasonal allergic rhinitis. A lead optimization program was started based on the discovery of the recently disclosed CRTh2 antagonist 2-(2-benzoyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid 5. An already favorable and druglike profile could be assessed for lead compound 5. Therefore, the lead optimization program mainly focused on the improvement in potency and oral bioavailability. Data of newly synthesized analogs were collected from in vitro pharmacological, physicochemical, in vitro ADME, and in vivo pharmacokinetic studies in the rat and the dog. The data were then analyzed using a traffic light selection tool as a visualization device in order to evaluate and prioritize candidates displaying a balanced overall profile. This data-driven process and the excellent results of the PK study in the rat (F = 44%) and the dog (F = 55%) facilitated the identification of 28 as a potent (IC50 = 6 nM), selective, and orally available CRTh2 antagonist.

  DOI：

  10.1021/jm400122f
• 作为产物：
  描述：

  对甲基苯肼 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 8-甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚
  参考文献：
  名称：

  二价配体方法可作为改善Dimebon体外抗阿尔茨海默氏多靶点分布的工具

  摘要：

  受二价配体概念的启发，我们准备了少量候选药物Dimebon的类似物。已显示它们比地美本更大程度地抑制AChE，Aβ42聚集和NMDA受体活化。其中一些化合物还可以在诱导细胞凋亡的条件下提高鸡神经元的存活率。

  DOI：

  10.1002/cmdc.201300263

文献信息

• COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION
  申请人：Medivation Technologies, Inc.

  公开号：US20150266884A1

  公开（公告）日：2015-09-24

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α 2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α 1B . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  氢化吡啶并[4,3-b]吲哚，吡啶[3,4-b]吲哚和氮杂七元[4,5-b]吲哚被描述。这些化合物可能与肾上腺素受体α2B结合并拮抗。这些化合物也可能与肾上腺素受体α1B结合并拮抗。这些化合物可能在治疗中发挥作用，例如（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠重吸收。这些化合物也可用于治疗对降低血压有反应或预期会有反应的疾病或症状。特别描述了使用这些化合物治疗心血管和肾脏疾病。
• [EN] 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DE 1,3,4,5-TÉTRAHYDRO-2H-PYRIDO[4,3-B]INDOLE POUR LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION DE TROUBLES ASSOCIÉS À DES AGRÉGATS DE TAU COMME LA MALADIE D'ALZHEIMER
  申请人：AC IMMUNE SA

  公开号：WO2019134978A1

  公开（公告）日：2019-07-11

  The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

  本发明涉及一类新化合物，可用于治疗、缓解或预防与Tau蛋白聚集相关的一组疾病和异常，包括但不限于神经原纤维缠结（NFTs），如阿尔茨海默病（AD）。
• [EN] CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS DE CARBOLINE POUVANT ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：ALZPROTECT

  公开号：WO2014207240A1

  公开（公告）日：2014-12-31

  The present invention relates to a compound according to Formula (A) or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or polymorph thereof, and its use.

  本发明涉及按照式（A）的化合物或其药学上可接受的盐、溶剂化合物、包合物、水合物或多晶形式，以及其用途。
• Synthesis and biological evaluation of novel γ-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists
  作者：Alexandre V. Ivachtchenko、Eugene B. Frolov、Oleg D. Mitkin、Volodymyr M. Kysil、Alexander V. Khvat、Ilya M. Okun、Sergey E. Tkachenko

  DOI：10.1016/j.bmcl.2009.04.128

  日期：2009.6

  Synthesis, biological evaluation and structure–activity relationships for a series of novel γ-carboline analogues of Dimebon™ are described. Among the studied compounds, γ-carbolines 38} and 314} have been identified as potent small molecule antagonists of histamine H1 (IC50 = 0.1 μM) and serotonin 5-HT6 (IC50 = 0.37 μM) receptors, respectively.

  描述了一系列新的Dimebon ™ γ-咔啉类似物的合成，生物学评估和结构-活性关系。在研究的化合物中，已确定γ-咔啉3 8}和3 14 }是组胺H 1（IC 50  = 0.1μM）和5-羟色胺5-HT 6（IC 50  = 0.37μM）受体的有效小分子拮抗剂。， 分别。
• Hexahydro-.gamma.-carboline derivatives and their salts
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US03983239A1

  公开（公告）日：1976-09-28

  Hexahydro-.gamma.-carboline derivatives of the formula: ##SPC1## Wherein R.sub.1 is methyl or ethyl, and R.sub.2 is hydrogen, methyl or ethyl, with proviso that when R.sub.1 is ethyl, R.sub.2 is hydrogen, and their pharmaceutically acceptable acid addition salts, which exhibit excellent psychotropic effect, and a process for the preparation thereof.

  公式为：##SPC1## 其中R.sub.1为甲基或乙基，R.sub.2为氢、甲基或乙基，但当R.sub.1为乙基时，R.sub.2为氢，以及它们的药用可接受酸盐，表现出优秀的精神药效，并提供其制备方法。